Neuromyelitis Optica Spectrum Disorder (NMOSD) Archives

CAR T-cell therapy in MS: in its infancy but highly anticipated

Presented By

Prof. Frauke Zipp, Johannes Gutenberg University Mainz, Germany

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:33

Ineffective response to EBV in MS not seen in similar diseases

Presented By

Dr Tilman Schneider-Hohendorf, University of Münster, Germany

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 12:01

Comparative effectiveness and safety of DMTs in NMOSD

Presented By

Dr Philippe-Antoine Bilodeau, Brigham and Women’s Hospital, MA, USA

Conference

ECTRIMS 2024

Type

Peer-reviewed article

18 November 2024 11:59

An update on evolving treatment algorithms for NMOSD and MOGAD

Presented By

Prof. Jeffrey Bennett, University of Colorado, CO, USA

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:09

Switching from rituximab to C5 complement inhibitors is safe in AQP4+ NMOSD

Trial

Phase 3, PREVENT, CHAMPION-NMOSD

Conference

MSMilan 2023

Type

Peer-reviewed article

4 December 2023 11:08

Ravulizumab effective in AQP4+ NMOSD

Presented By

Dr Sean Pittock, Mayo Clinic, NY, USA

Trial

Phase 3, CHAMPION-NMOSD

Conference

AAN 2023

Type

Peer-reviewed article

26 June 2023 20:28

Ravulizumab significantly reduced relapses in AQP4+ NMOSD

Presented By

Dr Sean Pittock, Mayo Clinic, MN, USA

Trial

Phase 3, CHAMPION-NMOSD

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:36

NMOSD patients are cognitively impaired regardless of serostatus

Presented By

Dr Martin Hümmert, Hannover Medical School, Germany

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 11:25

Evidence-based consensus on pregnancy in NMOSD

Presented By

Prof. Sandra Vukusic, University Hospital Lyon, France

Conference

ECTRIMS 2022

Type

Peer-reviewed article

20 December 2022 10:34

ECTRIMS 2022 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Conference

ECTRIMS 2022

15 November 2022 00:08

Sustained long-term efficacy and safety of satralizumab in NMOSD

Presented By

Prof. Jeffrey Bennett, University of Colorado Hospital, CO, USA

Trial

Phase 3, SAkuraSky; SAkuraStar

Conference

AAN 2022

Type

Peer-reviewed article

2 June 2022 15:29

Eculizumab, satralizumab, or inebilizumab for NMOSD?

Presented By

Prof. Dean Wingerchuk, Mayo Clinic Phoenix/Scottsdale, AZ, USA

Trial

Phase 3, N-MOmentum, PREVENT, SAkuraStar, SAkuraSky

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:37

Long-term efficacy of satralizumab for NMOSD

Presented By

Dr Ingo Kleiter, Ruhr-Universität Bochum, Germany

Trial

Phase 3, SAkuraStar, SAkuraSky

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:34

Long-term efficacy data: inebilizumab for NMOSD

Presented By

Prof. Bruce Cree, UCSF Multiple Sclerosis Center, CA, USA

Trial

Phase 3, N-MOmentum

Conference

ECTRIMS 2021

Type

Peer-reviewed article

9 December 2021 15:31

Satralizumab efficacious in AQP4-IgG-positive patients with NMOSD

Trial

Phase 3, SAkuraSky, SAkuraStar

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:30

Good long-term safety and efficacy of inebilizumab in NMOSD

Presented By

Prof. Bruce Cree, University of California San Francisco, CA, USA

Trial

Phase 3, N-MOmentum

Conference

EAN 2021

Type

Peer-reviewed article

18 August 2021 10:28

Decreased EDSS after plasma exchange in NMOSD

Presented By

Dr Enrique Gómez-Figueroa, National Institute of Neurology and Neurosurgery, Mexico

Conference

ECF 2020

Type

News article

16 December 2020 10:21

No support for IVIG as treatment of acute attacks in NMOSD

Presented By

Dr De-Cai Tian, Capital Medical University, China

Conference

ECF 2020

Type

News article

16 December 2020 10:20

Serum glial fibrillary acidic protein predicts relapses in NMOSD

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 17:06

Gut dysbiosis in NMOSD promotes CNS autoimmunity

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:46

NG-specific biomarkers differentiate NMOSD from MS

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:46

Eculizumab reduces long-term relapse risk in AQP4-positive NMOSD

Trial

Phase 3, PREVENT

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:45

Satralizumab lowers risk of severe relapse in NMOSD patients

Trial

SAkuraSky, SAkuraStar

Conference

MS Virtual 2020

Type

Peer-reviewed article

25 November 2020 16:45

Genetic association studies in NMOSD needed

Presented By

Dr Viktoria Papp, Aarhus University Hospital, Denmark

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 14:08

Eculizumab in NMOSD: the PREVENT study

Presented By

Dr Celia Oreja-Guevara, Hospital Clínico San Carlos, Spain

Trial

Phase 3, PREVENT

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 14:03

Long-term safety of satralizumab consistent with double-blind periods

Presented By

Prof. Benjamin Greenberg, University of Texas Southwestern Medical Center, USA

Trial

Phase 3, SAkuraSky; SAkuraStar

Conference

EAN 2020

Type

Peer-reviewed article

10 September 2020 13:58

Risk of hypogammaglobulinemia and rituximab

Presented By

Dr Susanna Hallberg, Karolinska Institute, Sweden

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 21:18

Late-breaking: Role for CSF markers in autoimmune astrocytopathies

Presented By

Dr Iris Kleerekooper, University College London, United Kingdom

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 20:13

Targeted therapies for NMOSD in development

Presented By

Dr Dean Wingerchuk, Mayo Clinic, Rochester, United States

Trial

Phase 3, PREVENT

Conference

ECTRIMS 2019

Type

Peer-reviewed article

8 November 2019 11:17

Promising results of novel NMOSD treatments

Conference

EAN 2019

Type

Peer-reviewed article

27 August 2019 09:40

Three very promising new treatments of NMOSD

Presented By

Dr Stacey Clardy & Prof. Bruce Cree

Trial

PREVENT, SAkuraSky

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 23:07

Immune tolerance by peptide-loaded tolerogenic dendritic cells

Expert

Dr Irati Zubizarreta, Institut d’Investigacions Biomediques August Pi Sunyer, Spain

Conference

AAN 2019

Type

Peer-reviewed article

30 July 2019 22:08